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Abstract
Background: A direct role of sodium channels in pain has recently been confirmed by establishing a monogenic link 
between SCN9A, the gene which encodes sodium channel Nav1.7, and pain disorders in humans, with gain-of-function 
mutations causing severe pain syndromes, and loss-of-function mutations causing congenital indifference to pain. 
Expression of sodium channel Nav1.8 in DRG neurons has also been shown to be essential for the manifestation of 
mutant Nav1.7-induced neuronal hyperexcitability. These findings have confirmed key roles of Nav1.7 and Nav1.8 in 
pain and identify these channels as novel targets for pain therapeutic development. Ranolazine preferentially blocks 
cardiac late sodium currents at concentrations that do not significantly reduce peak sodium current. Ranolazine also 
blocks wild-type Nav1.7 and Nav1.8 channels in a use-dependent manner. However, ranolazine's effects on gain-of-
function mutations of Nav1.7 and on DRG neuron excitability have not been investigated. We used voltage- and 
current-clamp recordings to evaluate the hypothesis that ranolazine may be effective in regulating Nav1.7-induced 
DRG neuron hyperexcitability.
Results: We show that ranolazine produces comparable block of peak and ramp currents of wild-type Nav1.7 and 
mutant Nav1.7 channels linked to Inherited Erythromelalgia and Paroxysmal Extreme Pain Disorder. We also show that 
ranolazine, at a clinically-relevant concentration, blocks high-frequency firing of DRG neurons expressing wild-type but 
not mutant channels.
Conclusions: Our data suggest that ranalozine can attenuate hyperexcitability of DRG neurons over-expressing wild-
type Nav1.7 channels, as occurs in acquired neuropathic and inflammatory pain, and thus merits further study as an 
alternative to existing non-selective sodium channel blockers.
Background
There is substantial evidence for a critical role of sodium
channels in acquired and inherited painful neuropathies,
and non-selective sodium channel blockers are among
first-line treatment for neuropathic and inflammatory
pain, although they result in significant side effects which
limits their clinical use [1]. The Nav1.7 sodium channel is
preferentially expressed in sensory and sympathetic neu-
rons and has been directly linked to painful disorders in
humans; genetic studies have identified gain-of-function
missense mutations within SCN9A, the sodium channel
gene that encodes Nav1.7, in patients with inherited
erythromelalgia (IEM), and a different set of gain-of-
function missense mutations has been found in patients
with paroxysmal extreme pain disorder (PEPD) [2,3].
Recently, loss-of-function mutations in Nav1.7 have been
identified in individuals with congenital and complete
inability to experience pain [2,3]. These studies provide
compelling and complementary evidence for the role of
this channel in pain signaling, and thus it has been con-
sidered to be a target for drug development.
Ranolazine is an anti-anginal drug which has been
shown to preferentially block cardiac late (persistent)
sodium current at concentrations that do not inhibit the
peak transient current [4-6]. Ranolazine shortens the
action potential duration in cardiac myocytes from mice
with a long Q-T interval (LQT) Nav1.5 knock-in mutation
but not from wild type (WT) mice [6]. Ranolazine acts as
an open and inactivated-state blocker [7-9], its binding
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site overlaps with the local anesthetic receptor in domain
4/transmembrane segment 6 (DIV/S6) of voltage-gated
sodium channels [6,8], and ranolazine appears to be a
more effective anti-anginal agent compared to lidocaine
[10]. Ranolazine has been shown to inhibit WT Nav1.7
and Nav1.8 in a use-dependent manner [8,9], and thus
might be useful for treatment of hyperexcitability disor-
ders of sensory systems, for example neuropathic and
inflammatory pain caused by up-regulated expression of
Nav1.7 [11,12].
We used voltage-clamp recordings to study the block of
WT and IEM- and PEPD-related Nav1.7 mutations by
ranolazine, and show a comparable block of peak and
ramp currents of WT and mutant Nav1.7 channels. We
also used current-clamp recordings to study firing of dor-
sal root ganglion (DRG) neurons transfected with WT
and mutant Nav1.7 channels and show that ranolazine, at
a clinically-relevant concentration, blocks high-frequency
firing of DRG neurons expressing WT but not mutant
Nav1.7 channels. These data are discussed in the context
of using ranolazine for treatment of pain disorders.
Results
To verify the typical biophysical signatures in HEK 293
cells for the hNav1.7 mutant channels, the voltage-depen-
dence of activation and fast-inactivation were determined
for the IEM mutant L858H and the PEPD mutant V1298F
and compared to WT channels. IEM mutations typically
result in a hyperpolarized shift of the voltage-dependence
of activation making the mutant channels easier to open
in response to small depolarizations. Consistent with
this, the V1/2 of activation for the L858H mutant channel
(V1/2 = - 31.9 ± 1.2 mV, k = 9.2 ± 0.3; n = 11) was signifi-
cantly (p < 0.001) shifted 8 mV in the hyperpolarized
direction (Figure 1G) compared to WT channels (V1/2 = -
23.8 ± 1.7 mV, k = 6.9 ± 0.5; n = 12). The V1/2 of activation
for the PEPD mutation V1298F (V1/2 = -21.6 ± 1.4 mV, k =
7.4 ± 0.4; n = 18) was not significantly different from WT
channels. In contrast, the biophysical signature for PEPD
mutations is a depolarizing shift of the voltage-depen-
dence of fast-inactivation predicting a greater availability
of channels to open under conditions of sustained depo-
larizations. As expected, the V1/2 of fast-inactivation for
the V1298F mutant (V1/2 = -63.3 ± 1.7 mV, k = 6.0 ± 0.3; n
= 18) was significantly (p < 0.001) shifted 15.7 mV in the
depolarized direction (Figure 1H) compared to WT
channels (V1/2 = -79.0 ± 2.1 mV, k = 6.8 ± 0.4; n = 12). The
fast-inactivation V1/2 for the IEM mutation L858H (V1/2 =
-75.9 ± 1.9 mV, k = 8.5 ± 0.9; n = 11) was not significantly
different from WT.
Ranolazine has recently been shown to block WT
Nav1.7 and Nav1.8 channels [8,9] in a voltage-dependent
manner, indicating higher affinity against inactivated
channels. We examined whether either the L858H IEM
mutation or the V1298F PEPD mutation show a differen-
tial sensitivity to ranolazine block at a holding potential
(Vhold) of -120 mV or after 10-sec conditioning depolar-
izing potentials of -100 mV, -80 mV, -60 mV or -40 mV,
c o m p a r e d  t o  WT  c h a n n e l s .  T o  m i n i m i z e  t h e  e f f e c t  o f
slow changes in channel properties over time after
achieving whole-cell dialysis, each cell was exposed to
only one concentration of ranolazine. The fractional
block to ranolazine at the various conditioning potentials
was obtained by dividing the peak response to ranolazine
by the peak response obtained during the baseline period
as illustrated in figure 2. The dose-response dataset for a
given conditioning potential was obtained by averaging 3-
6 independent cells for each ranolazine concentration. As
shown in figure 3A, the IC50 values for WT channels,
derived by fitting a dose-response curve to the average
block over six concentrations of ranolazine spanning the
range of 0.3 μM to 100 μM, was voltage-dependent. The
block was weakest for resting channels (IC50 = 175 μM at
Vhold = -120 mV), and became stronger with increasing
depolarizing conditioning potentials (IC50 = 34 μM at
Vcond = -60 mV). For L858H mutant channels, our data
indicate (Figure 3B) that ranolazine block is less effective
for resting channels (IC50 = 700 μM at Vhold = -120 mV)
but the increase with depolarization still occurs resulting
in similar block as for WT (IC50 = 31 μM at Vcond = -60
mV). For the V1298F mutant channels (Figure 3C), the
IC50 for ranolazine block is similar to WT at both resting
(IC50 = 110 μM at Vhold = -120 mV) as well as depolar-
ized (IC50 = 39 μM at Vcond = -60 mV) potentials. The
parameters of the fitted dose-response curves for WT,
L858H and V1298F channels are compiled in Table 1. The
fit comparison statistic in Origin reports that the IC50 val-
ues at depolarized Vcond potentials -60 mV and -40 mV
were significantly different than the IC50  for resting
(Vhold -120 mV) values comparing within WT, L858H
and V1298F data. This same statistic comparing between
WT and either L858H or V1298F reports no significantly
enhanced block by ranolazine at either resting (Vhold -
120 mV) or depolarized (Vcond -60 mV or -40 mV) volt-
ages.
Therapeutically achievable concentrations of ranola-
zine are lower (2-8 uM) than the reported IC50 for
Nav1.7 channels in HEK 293 cells, and in cardiac cells are
thought to work by differentially blocking the persistent
current of Nav1.5 while sparing the peak current [4-6].
Because of slow closed-state inactivation, Nav1.7 chan-
nels respond to a slow voltage ramp depolarization with a
current near resting potential of DRG neurons (ramp cur-
rent), which is thought to boost natural weak stimuli [13].
In addition to the shifts in the voltage-dependence ofEstacion et al. Molecular Pain 2010, 6:35
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Figure 1 Voltage-dependence of WT and the L858H and V1298F mutant channels. (A) Superimposed activation traces recorded from a repre-
sentative HEK + hNav1.7r-WT expressing cell. (Average peak current is -4.2 ± 0.7 nA, n = 12) (B) Superimposed fast-inactivation traces recorded from 
the same cell as in (A). (C) Superimposed activation traces recorded from a representative HEK + hNav1.7r-L858H expressing cell. (Average peak cur-
rent is -2.3 ± 0.3 nA, n = 12). (D) Superimposed fast-inactivation traces recorded from the same cell as in (C). (E) Superimposed activation traces record-
ed from a representative HEK + hNav1.7r-V1298F expressing cell (Average peak current is -1.9 ± 0.3 nA, n = 18). (F) Superimposed fast-inactivation 
traces from the same cell as in (E). Insets illustrate the voltage pulse protocols for activation and fast-inactivation. The bold bars indicate the portion 
of the data sweeps displayed in this figure. (G) Normalized conductance-voltage (G-V) curves are constructed from the averages of individual HEK 293 
cells expressing WT (black squares, n = 12), the IEM mutation L858H (red circles, n = 12), or the PEPD mutation V1298F (blue triangles, n = 18). (H) 
Normalized fast-inactivation curves are constructed from the averages of the same cells as in panel G.Estacion et al. Molecular Pain 2010, 6:35
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activation or fast-inactivation of IEM and PEPD muta-
tions, ramp currents are significantly bigger for IEM and
PEPD mutant channels, compared to WT [2]. Thus, we
examined whether ranolazine could differentially block
the signature Nav1.7 ramp current. As shown in figure 4,
10 μM ranolazine did not significantly reduce peak
inward ramp current in WT-, L858H-, or V1298F-
expressing HEK 293 cells compared to cells exposed to
vehicle control. There was no evidence for a differential
block of ramp currents in L858H or V1298F mutant
expressing cells compared to hNav1.7r-WT expressing
cells.
Use-dependent block was examined to see whether
either the L858H IEM mutant or the V1298F PEPD
m utant showed a differen tial response to this prot oc ol
compared to WT channels. The example in Figure 5
shows the change in peak response to a train of 20 pulses
applied to HEK 293 cells expressing WT channels at 5 Hz
both before (Figure 5A) and after exposure to 10 μM
ranolazine (Figure 5B). The graph in Figure 5C shows the
relative block that occurs during the pulse train, obtained
by dividing the peak of each pulse by the peak of the first
pulse, for the data in panels 5A and 5B. In the absence of
the drug, WT channels show use-dependence at frequen-
cies greater than 5 Hz, suggesting that there is some accu-
mulation of inactivated channels as the recovery period
between pulses is shortened. After exposure to 10 μM
ranolazine, there was a significant increase in the use-
dependent reduction at all stimulation frequencies. For
the L858H IEM mutant channels, (Figure 5E) there was
notably more basal use-dependence at all stimulation fre-
quencies. 10 μM ranolazine also caused a small but sig-
Table 1: Summary of voltage-dependent ranolazine block
WT L858H V1298F
Vhold = -120 mV 175 μM, R = 0.44 700 μM, R = 0.96 110 μM, R = 0.55
Vcond = -100 mV 107 μM, R = 0.79 164 μM, R = 0.93 120 μM, R = 0.83
Vcond = -80 mV 53 μM, R = 0.92 60 μM, R = 0.98 81 μM, R = 0.61
Vcond = -60 mV 34 μM, R = 0.99 31 μM, R = 0.97 39 μM, R = 0.74
Vcond = -40 mV 31 μM, R = 0.99 21 μM, R = 0.99 20 μM, R = 0.99
Figure 2 Voltage-dependence of ranolazine block: Example traces. The voltage-dependence of ranolazine block was determined by utilizing a 
ten-second conditioning pulse protocol as described in Methods. After the protocol was performed once (black traces), the cells were exposed to a 
single concentration of ranolazine and then the protocol was repeated (red traces). These data traces were obtained from an HEK + hNav1.7r-L858H 
expressing cell treated with 10 μM Ranolazine. The fraction of ranolazine block was determined at each conditioning potential by dividing the peak 
current in the presence of ranolazine by the baseline peak current.Estacion et al. Molecular Pain 2010, 6:35
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Figure 3 Voltage-dependence of ranolazine block of hNav1.7r-WT 
and L858H and V1298F mutants: Dose-response curve fits. The extent 
of ranolazine block for each cell was determined for conditioning po-
tentials ranging from the holding potential of -120 mV (resting block) 
to Vcond of -40 mV (inactivated block). Each cell was exposed to only 
one concentration of ranolazine. The dose-response curve for each 
conditioning potential (see legend symbols) was obtained by fitting a 
single-site binding curve to the average current block (3-9 cells/point).
Figure 4 Ranolazine block of ramp currents. The response to slow 
gradual depolarization (ramp) stimulus protocol (-100 mV to +20 mV 
over 600 msec) from representative cells is normalized to the peak in-
ward current for that cell as described in Methods. Separate cells were 
exposed to either 0.1% HCl vehicle control (grey line) or 10 μM ranola-
zine (bold line). In each panel the two traces are overlaid to compare 
the response to ranolazine. (A) HEK 293 cells expressing WT show a 
peak ramp response of 0.58 ± 0.15% and the voltage peaks at -43.0 ± 
1.2 mV in the presence of 0.1% HCl vehicle control (n = 3). In the pres-
ence of 10 μM ranolazine (n = 4), the peak ramp response was 0.79 ± 
0.22% and the voltage peaks at -48.0 ± 3.9 mV. (B) HEK 293 cells ex-
pressing, the IEM mutant L858H show a peak ramp response of 4.48 ± 
1.13% and the voltage peaks at -55.8 ± 2.2 mV in the presence of 0.1% 
HCl vehicle control (n = 5). In the presence of 10 μM ranolazine (n = 4), 
the peak ramp response was 3.31 ± 0.60% and the voltage peaks at -
54.1 ± 2.0 mV. (C) HEK 293 cells expressing the PEPD mutant V1298F 
show a peak ramp response of 1.05 ± 0.21% and the voltage peaks at -
48.5 ± 2.2 mV in the presence of 0.1% HCl vehicle control (n = 8). In the 
presence of 10 μM ranolazine (n = 7), the peak ramp response was 0.84 
± 0.11% and the voltage peaks at -49.7 ± 2.7 mV.Estacion et al. Molecular Pain 2010, 6:35
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Figure 5 Frequency-dependence of use-dependent block of Nav1.7 currents by ranolazine. Trains of twenty 30 msec duration pulses to -10 mV 
from a holding potential of -120 mV were applied at five different frequencies and were performed both before and after exposure to 10 μM ranola-
zine. Example traces from a HEK 293 cell expressing WT channels are shown in panels A and B. The peak for each pulse is normalized to the peak of 
the first pulse, and the values are plotted in panel C. The use-dependent block, defined as the ratio of the peak from the 20th pulse normalized to the 
peak of the first pulse, was determined for each cell and the averages are plotted with the basal responses shown in grey and the ranolazine responses 
shown in solid bars. In each panel the two datasets are shown to compare the response to ranolazine in cells expressing WT (panel D, n = 5), the IEM 
mutant L858H (panel E, n = 4), or the PEPD mutant V1298F (panel F, n = 7), channels.Estacion et al. Molecular Pain 2010, 6:35
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nificant additional use-dependent response at all
frequencies. The V1298F PEPD mutant channels, how-
ever, showed reduced basal use-dependence compared to
WT channels while still showing the small but significant
increase in response to 10 μM ranolazine (Figure 5F).
We directly tested whether ranolazine could reduce
excitability of DRG neurons transfected with either WT
or the hyperexcitability-inducing mutations L858H or
V1298F. The majority of DRG neurons transfected with
WT channels fire 1-2 action potentials in response to a
one second depolarizing stimuli, while neurons trans-
fected with Nav1.7 channels carrying IEM or PEPD
mutations fire repetitively [14-18]. As shown in Figure 6
A, there was no obvious effect of 10 μM ranolazine on
low frequency firing WT-expressing DRG neurons. In
contrast, a few WT-expressing DRG neurons showed a
high frequency firing phenotype and ranolazine clearly
seemed to attenuate the response to the stronger depolar-
izing current stimuli.(Figure 6B). Thus, we selected neu-
rons that fired multiple action potentials to study the
effect of ranolazine on DRG neuron excitability. The
averaged data shown in Figure 7 are compiled from the
subset of neurons that fired at least five action potentials,
recorded before ranolazine application in response to any
current injection step, over the entire range of 50 to 1000
pA. The effect of 10 μM ranolazine treatment on DRG
neurons transfected with WT is shown in Figure 7 A.
Before ranolazine, the cells exhibited a smoothly increas-
ing number of action potentials elicited in response to
increasing current injections reaching an average of 14
spikes during the 1 second long stimulus. After ranola-
zine, there was no change in the threshold to first spike or
in the number of spikes elicited. For DRG neurons trans-
fected with WT Nav1.7 channels, the main effect of rano-
lazine was to attenuate the number of spikes elicited at
the higher current stimulation range. The number of
spikes elicited for current injections of 600 pA or greater
was significantly reduced by 10 μM ranolazine. In con-
trast, there was no effect of ranolazine on the number of
spikes elicited at any stimulus level on DRG neurons
expressing either the L858H IEM mutant (Figure 7B) or
the V1298F PEPD mutant (Figure 7C).
Discussion
Ranolazine is a relatively new anti-anginal drug which
preferentially blocks late but not peak Nav1.5 sodium cur-
rents at clinically-relevant concentrations [6], and has
been shown to shorten the action potential duration in
cardiac myocytes expressing an LQT5 Nav1.5 mutation
but not wild type cardiac channels [6]. We evaluated
ranolazine as a blocker of wild-type Nav1.7 channels and
of mutant Nav1.7 channels that underlie two different
neuropathic human pain disorders, IEM and PEPD, and
assessed its ability to reduce excitability of DRG neurons
that express WT or pain-causing mutant Nav1.7 chan-
nels. Using voltage-clamp we show here that ranolazine
blocks WT and mutant Nav1.7 channels in a voltage-
dependent manner, with greater block of inactivated
channels, but with comparable effectiveness against WT
and mutant Nav1.7 channels. We also show that ranola-
zine does not preferentially block ramp currents, com-
pared to peak currents. Using current-clamp we show
that ranolazine, at a clinically-relevant concentration,
attenuates excitability of DRG neurons expressing WT
but not the two mutant Nav1.7 channels examined here.
These data suggest that ranolazine may be useful for
treatment of some pain conditions in which up-regulated
Nav1.7 expression, or modulation of this channel, con-
tributes to DRG neuron hyperexcitability (see [11,12,19]).
The low affinity block of hNav1.7 channels in the rest-
ing state (hyperpolarized holding potentials more nega-
tive than -100 mV) is in agreement with previously
reported data [8,9], in which little block was observed by
the highest drug concentration used. We have now
extended this finding to two pain-linked mutations of
hNav1.7: the IEM disease-causing mutation L858H that
exhibits a hyperpolarizing shift of the voltage-depen-
dence of activation with no effect on fast-inactivation
[20], and the PEPD disease-causing mutation V1298F
that exhibits a depolarizing shift in the voltage-depen-
dence of fast-inactivation with little effect on activation
([21,22]). Ranolazine appears to share a binding site with
local anesthetics (LA) in sodium channels Nav1.4 [8] and
Nav1.5 [6]. The reduced affinity for ranolazine to the
closed-state of hNav1.7 reported here and by Wang et al.
(2008) suggests that ranolazine access to its site is
occluded when the hNav1.7 channels are hyperpolarized.
Neither the L858H or V1298F mutant channels at rest
(holding potential of -120 mV) show a reduced block by
ranolazine, compared to WT channels (Table 1), suggest-
ing no significant mutation-induced conformational
change of the structure of the channel.
Our results show that the apparent affinity for ranola-
zine block of hNav1.7 is voltage-dependent, with increas-
ing effectiveness of channel block with depolarizing
conditioning pulses. The conditioning pulse protocol
used here utilized a 100 msec pulse to -120 mV to recover
unblocked channels from fast-inactivation which will
then be activated with a strong test depolarization pulse.
The study by Wang et al. (2008) used 95 msec recovery
pulse to -120 mV and reports similar IC50 values (59.9 ±
3.8 μM with Vcond = -70 mV) in close agreement with
our study (34 μM with Vcond = -60 mV). In contrast, the
study by Rajamani et al. (2008) utilized a 20 msec recov-
ery pulse and reported a much lower IC50 value (3.25 μMEstacion et al. Molecular Pain 2010, 6:35
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with Vcond = -70 mV). We have previously reported that
the time constant for repriming of hNav1.7 channels at -
120 mV is about 20 msec [13,23], so only about 63% of the
channels available to recover will have done so with a 20
m s ec  r ec o v e ry  p u l s e .  A l t h o u g h  t h e  1 0 0  m s e c  r ec o v e ry
pulse is effective at differentiating slow-inactivation from
fast-inactivation, the kinetics of ranolazine unbinding to
closed (Vm = -120 mV) channels may affect the IC50 val-
ues reported here. The differences in the IC50  values
between our data and previous reports might be
explained by these differences in recording protocols.
Figure 6 Example responses to ranolazine from WT-expressing DRG neurons. (A) Traces illustrating the response to 1 second duration current 
injections of 200pA, 400pA, and 600pA both before (upper row) and after (lower row) exposure to 10 μM ranolazine are shown from a DRG neuron 
transfected with hNav1.7-WT channels. This phenotype, showing low frequency firing, typically occurs in 5 of 6 WT-expressing DRG neurons chosen 
for recording. (B) Traces in the same format as panel A recorded from a high frequency firing WT-expressing DRG neuron.Estacion et al. Molecular Pain 2010, 6:35
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Enhanced ranolazine block with more depolarized con-
ditioning potentials suggests that the higher affinity inter-
action of ranolazine is with open or inactivated states of
the Nav1.7 channel. Wang et al. (2008) used mutational
ablation of the fast-inactivation gate to argue that ranola-
zine preferentially binds to the open state of hNav1.7
channels and that the fast-inactivated conformation is
not required for ranolazine block. At the conditioning
potential of -60 mV, close to typical resting membrane
potential of small DRG neurons [14-18,24,25], there was
no apparent change in the effectiveness of ranolazine
block for either of these mutant channels compared to
wild-type channels. The apparent similarity of ranolazine
block of WT or mutant Nav1.7 channels with either
hyperpolarized activation and enhanced slow-inactiva-
tion (L858H [20]), or depolarized fast-inactivation and
impaired slow-inactivation (V1298F [21,22]), suggest that
the rate-limiting step for ranolazine-induced block of
peak sodium currents may depend on the early transi-
tions of the channels from the closed to the open state
and less on the fully-activated or fully-inactivated chan-
nel states.
The ability of Nav1.7 to produce a current in response
to small, slow depolarizations (ramp current) [13], thus
boosting weak stimuli, contributes to the role of Nav1.7 as
a threshold channel [26]. Most mutations that underlie
IEM and PEPD increase amplitude of ramp currents of
mutant Nav1.7 channels even when the peak currents
were either unchanged or even reduced [2]. Because
ranolazine is more effective at blocking late sodium cur-
rent than peak current [4-6], we tested the hypothesis
that Nav1.7 ramp currents may be preferentially blocked
by ranolazine. We show here that ranolazine, at the clini-
cally-relevant concentration of 10 μM, does not differen-
t ia ll y bloc k  r am p curr e n ts pr oduc ed by m uta n t  N a v1.7
channels compared to WT. Together with our results
showing similar IC50  of ranolazine block of WT and
mutant Nav1.7 peak currents, these data suggests that
ranolazine may not have a preferential effect in blocking
mutant Nav1.7-induced DRG hyperexcitability.
Use-dependent loss of current in the absence of block-
ers suggests that there is progressive accumulation of
channels into slow-inactivated states. The L858H mutant
exhibits the most use-dependence in the absence of rano-
lazine (Figure. 5E) which is predicted by its enhanced
slow-inactivation [20], while the V1298F mutant exhib-
ited the least use-dependence in the absence of drug (Fig-
ure. 5F) consistent with the depolarized shift of fast- and
slow-inactivation curves by this PEPD mutant [21,22].
The additional drug-induced use-dependence was small
and constant over all stimulation frequencies for both the
L858H and V1298F mutant channels. In contrast, ranola-
Figure 7 Effect of ranolazine on the excitability of DRG neurons 
expressing WT, L858H or V1298F channels. Action potentials were 
recorded in current-clamp mode from DRG neurons transfected with 
WT (panel A), the IEM mutant L858H (panel B), or the PEPD mutant 
V1298F (panel C), channels as described in the Methods section. The 
number of action potentials elicited during current injections of 1-sec 
duration ranging from 50 pA to 1000 pA in 50 pA increments are 
counted both before and then again after exposure to 10 μM ranola-
zine. In this figure, cells whose response did not exceed 5 spikes were 
removed to compare just the high firing cells. The average number of 
action potentials elicited at each current injection level are plotted be-
fore (grey) and after 10 μM ranolazine (solid) exposure. In each panel 
the two datasets are shown to compare the response to ranolazine in 
cells expressing WT (panel A, n = 10), the IEM mutant L858H (panel B, 
n = 4), or the PEPD mutant V1298F (panel C, n = 5), channels.Estacion et al. Molecular Pain 2010, 6:35
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zine showed increased use-dependent block with higher
frequency stimulation on WT channels (Figure 5D).
Ranolazine block of sodium channels in HEK 293 cells
may not capture the full effect in native neurons. There-
fore, we directly tested the effect of ranolazine on DRG
neuron firing. Our data show a significant ranolazine-
induced attenuation of neuronal excitability in DRG neu-
rons expressing WT channels (Figure. 7A). The effect of
ranolazine (at 10 μM) did not offset the hyperexcitability
induced by the two Nav1.7 disease-causing mutants. Pre-
viously, we have shown that the presence of Nav1.8 is
important for the manifestation of mutant Nav1.7 effects
on neuronal excitability [18]. While ranolazine can block
Nav1.8 channels with an IC50 similar to that of Nav1.7 [9],
the effect on Nav1.8 is not enough to attenuate the
mutant Nav1.7-induced neuronal hyperexcitability.
The reduction of firing in WT expressing DRG neurons
only occurred with stronger current injections which
would cause greater depolarization during the current
injection. The combination of increasing ranolazine
blocking effectiveness with depolarization and the use-
dependent inhibition of Nav1.7 and other ion conduc-
tances in this select group of neurons might explain this
attenuation of high firing rates. It is important to note
that the cells that are transfected with WT channels on
average fire at a lower frequency, compared to neurons
that are transfected with mutant Nav1.7 channels [14-
18,22,27]. In order to measure the effect of ranolazine on
DRG neurons expressing WT channels, we selected WT-
transfected neurons that fire at higher frequency com-
pared to average transfected neurons, and it is reasonable
to assume that these high-frequency firing neurons may
express a different complement of ion channels than the
average transfected neuron. Ranolazine, which is known
to block other ion channels albeit with different kinetics
compared to the block of late sodium currents [28], may
block ion conductances that are differentially expressed
in the WT-transfected high frequency-firing neurons
reported here, leading to the differential effect on WT-
transfected neurons compared to mutant-transfected
neurons.
Conclusions
Our data showing ranolazine block of high frequency fir-
ing of DRG neurons expressing WT hNav1.7 channels
suggest that ranolazine may provide relief from pain asso-
ciated with hyperexcitability of DRG neurons expressing
WT Nav1.7 channels. Indeed, ranolazine has been shown
to ameliorate pain behavior in animal models of acquired
neuropathic pain, although pain relief was short-lived,
lasting only 30-90 min depending on oral or intraperito-
neal delivery of the drug, and was more effective against
cold-induced pain than mechanical allodynia [29]. Rano-
lazine appears to be a safe drug for human patients [30],
and does not induce ataxic effects in animals [29], and its
utility for neuropathic and inflammatory pain treatment
merits further study.
Materials and methods
Voltage-clamp electrophysiology
The L858H (IEM, [20,31]) and V1298F (PEPD, [21,22,32])
mutations were introduced into a TTX-resistant (TTX-R)
version of human Nav1.7 cDNA (hNav1.7R, will be
referred to as WT, hereinafter) using QuickChange XL
site-directed mutagenesis (Stratagene, La Jolla, CA).
Transfected HEK 293 cells, grown under standard culture
conditions (5% CO2, 37°C) in Dulbecco's modified Eagle's
medium supplemented with 10% fetal bovine serum,
were treated with G418 for several weeks to derive stable
cell lines that express the mutant channels as described
previously [33,34]. Use of stable cell lines reduces vari-
ability in terms of current expression, and lends itself to
pharmacological profiling on an automated patch-clamp
platform, PatchXpress (Molecular Dynamics, Union City,
CA).
Whole-cell voltage-clamp recordings were performed
on isolated HEK 293 cells stably expressing WT or L858H
or V1298F mutant channels at room temperature
(~21°C). Electrodes were pulled from 1.6 mm O.D. boro-
silicate glass micropipettes (WPI, Sarasota, FL) and had a
resistance of 1-2 MΩ when filled with pipette solution,
which contained (in mM): 140 CsF, 10 NaCl, 10 HEPES, 1
EGTA (pH 7.3 with CsOH, adjusted to 320 mOsm with
dextrose). The extracellular solution contained (in mM):
140 NaCl, 3 KCl, 1 MgCl2, 1 CaCl2, 10 HEPES (pH 7.3
with NaOH, adjusted to 320 mOsm with dextrose). Volt-
age-clamp currents were recorded 5 min after establish-
ing whole-cell configuration on an Axopatch 200B
amplifier (Molecular Devices, Sunnyvale, CA) and stored
via a Digidata 1440A A/D converter (Molecular Devices)
at an acquisition rate of 50 kHz with a lowpass Bessel fil-
ter setting of 10 kHz. Voltage errors were minimized with
80-95% series resistance compensation, and only cells
with <3 mV voltage error after compensation were
included for analysis. When appropriate, linear leak cur-
rents and capacitance artifacts were subtracted out using
the P/N method provided by Clampex (Molecular
Devices) acquisition software. Clampfit (Molecular
Devices) and Origin (Microcal Software, Northhampton,
MA) were used for data analysis. Data are expressed as
means ± standard error (SEM). Statistical significance
was determined by Student's t-test. For datasets in which
data were collected from the same cell before and then
after exposure to ranolazine (use-dependence in voltage-
clamp, action potential firing in current-clamp) a paired
Student's t-test was performed.Estacion et al. Molecular Pain 2010, 6:35
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The slow ramp protocol smoothly varies the command
potential from -100 mV to 20 mV over 600 msec (0.2 mV/
msec). At this ramp rate fast Na-channels such as Nav1.1,
Nav1.2 and Nav1.6 undergo complete closed-state inacti-
vation and do not produce an inward current in response
to this stimulation protocol. hNav1.7, however, has
slowed closed-state inactivation kinetics and can still
exhibit a signature inward current during the slow ramp
[13]. To compare between cells, the ramp response is
scaled by the scalar value of the peak activation I-V
response (e.g. for a cell with -1500pA peak current, its
slow ramp will be divided by 1500). This maintains the
convention that inward currents are shown as downward
deflections in figures. The magnitude of the peak as well
as the voltage at peak are determined for each cell. These
values are averaged by channel type and compared using
Student's t-test.
For voltage-clamp studies examining the dose-response
to ranolazine treatment, stock solutions of ranolazine
(Supplied by Gilead Sciences Inc.) with a concentration of
10 mM were prepared in 0.1N HCl aqueous solution.
Studies were performed in extracellular solution contain-
ing 0.001N HCl (control) or working stock concentra-
tions of ranolazine prepared freshly in 0.1N HCl and then
diluted 1:100 in extracellular bath solution to give the
indicated drug final concentrations. The recordings were
obtained using the PatchXpress (Molecular Devices)
automated patch-clamp system. The effect of ranolazine
on the WT and L858H and V1298F mutant channels was
tested from the resting and inactivated states. To deter-
mine the voltage-dependence of ranolazine block, the
voltage clamp protocol was as follows: the membrane
potential was held at conditioning potentials that varied
from -120 mV (resting block) to -40 mV (inactivated
block) for 10 sec to equilibrate Nav1.7 channels in the
presence of vehicle (HCl) or ranolazine in the bath solu-
tion; the membrane potential was then pulsed to -120 mV
for 100 msec to allow channels not bound by drug to
recover from fast-inactivation, and then given a 20 msec
test pulse to 0 mV to elicit current from available chan-
nels. To control for time-dependent changes in current
expression, independent cells were exposed to only one
test concentration of ranolazine or vehicle at a consistent
time after initiation of whole-cell recording. The
response was normalized to the currents elicited from the
same protocols applied just before compound addition,
and data expressed as fraction of current remaining.
These normalized responses from 3-8 independent cells
for each ranolazine concentration were averaged and
plotted to make a dose-response curve. The half maximal
inhibitory concentration (IC50) of ranolazine for WT and
mutant channels were obtained by fitting the data at each
conditioning potential using the Dose Response function
in Origin. Statistical comparisons of these fits were per-
formed using the compare data function in Origin. Dif-
ferences are considered significant when p < 0.05.
Dorsal root ganglia neuron isolation and transfection
DRG from Sprague Dawley rat pups (P1-P5) were isolated
and then cultured as previously described [35]. Either
WT or mutant (L858H or V1298F) channels were tran-
siently transfected into DRG neurons, along with
enhanced-GFP, by electroporation with a Nucleofector II
(Amaxa, Gaithersburg, MD) using Rat Neuron Nucleo-
fector Solution and program G-013 as previously
described [35]. The ratio of sodium channel to GFP con-
structs was 5:1. The transfected neurons were allowed to
recover for 5 minutes at 37°C in 0.5 ml of Ca2+-free
DMEM containing 10% fetal calf serum. The cell suspen-
sion was then diluted with DRG media containing 1.5
mg/ml bovine serum albumin and 1.5 mg/ml trypsin
inhibitor, 80 μl was plated on 12 mm circular poly-D-
lysine/laminin precoated coverslips (BD Biosciences,
Bedford, MA) and the cells incubated at 37°C in 5% CO2
for 30 min. DRG media (1 ml/well), supplemented with
50 ng/ml each of mNGF (Alomone Labs, Jerusalem,
Israel) and GDNF (Peprotec, Rocky Hill, NJ), was then
added and the cells maintained at 37°C in a 5% CO2 incu-
bator.
Current-clamp electrophysiology
Whole-cell current-clamp recordings were performed
using the Axopatch 200B amplifier, digitized using the
Digidata 1440A interface and controlled using pCLAMP
software. The bath solution for current clamp recordings
contained (in mM): 140 NaCl, 3 KCl, 2 MgCl2, 2 CaCl2,
and 10 HEPES, pH 7.3 with NaOH (adjusted to 315
mOsm with dextrose). The pipette solution contained (in
mM): 140 KCl, 0.5 EGTA, 5 HEPES, and 3 Mg-ATP, pH
7.3 with KOH (adjusted to 300 mOsm with dextrose).
The junction potential between these two solutions given
by JPcalc was 5 mV but no correction was applied for cur-
rent-clamp experiments. Recordings were performed on
transfected presumptive nociceptive neurons based on
the morphology of small diameter (20-25 μm) round cell
bodies that also exhibited green fluorescence. All record-
ings were performed between 20 hr-50 hr post-transfec-
tion. Cover slips were transferred to a perfusable
chamber (Warner Instruments, Hamden, CT) and all
recordings were initiated within an hour. Whole-cell con-
figuration was obtained in voltage-clamp mode before
proceeding to the current-clamp recording mode. Cells
with stable (< 10% variation) resting membrane potentials
(RMPs) more negative than -35 mV and overshooting
action potentials (>85 mV RMP to peak) were used for
further data collection. Action potential frequency was
determined by quantifying the number of action poten-Estacion et al. Molecular Pain 2010, 6:35
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tials elicited in response to depolarizing current injec-
tions of 1 second duration.
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